Morgan Stanley (NYSE:MS – Get Free Report) was downgraded by research analysts at Hsbc Global Res from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.
A number of other equities analysts also recently commented on the company. Jefferies Financial Group upped their target price on Morgan Stanley from $120.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Citigroup upped their target price on Morgan Stanley from $105.00 to $135.00 and gave the company a “neutral” rating in a report on Monday. UBS Group upped their target price on Morgan Stanley from $102.00 to $112.00 and gave the company a “neutral” rating in a report on Tuesday, October 8th. Wells Fargo & Company upgraded Morgan Stanley from an “underweight” rating to an “equal weight” rating and upped their target price for the company from $107.00 to $142.00 in a report on Friday, November 15th. Finally, HSBC downgraded Morgan Stanley from a “buy” rating to a “hold” rating and upped their target price for the company from $128.00 to $131.00 in a report on Tuesday. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $115.63.
View Our Latest Stock Report on MS
Morgan Stanley Stock Down 0.1 %
Morgan Stanley (NYSE:MS – Get Free Report) last released its quarterly earnings data on Wednesday, October 16th. The financial services provider reported $1.88 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.31. The firm had revenue of $15.38 billion during the quarter, compared to analyst estimates of $14.27 billion. Morgan Stanley had a return on equity of 12.58% and a net margin of 10.64%. On average, analysts forecast that Morgan Stanley will post 7.32 earnings per share for the current fiscal year.
Insider Activity at Morgan Stanley
In other Morgan Stanley news, Director Stephen J. Luczo sold 60,000 shares of the firm’s stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $119.17, for a total value of $7,150,200.00. Following the transaction, the director now directly owns 138,363 shares of the company’s stock, valued at approximately $16,488,718.71. This trade represents a 30.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.24% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. Northwest Investment Counselors LLC purchased a new position in Morgan Stanley in the 3rd quarter worth approximately $26,000. Opal Wealth Advisors LLC purchased a new stake in shares of Morgan Stanley during the 2nd quarter worth $25,000. POM Investment Strategies LLC lifted its stake in shares of Morgan Stanley by 1,147.6% during the 2nd quarter. POM Investment Strategies LLC now owns 262 shares of the financial services provider’s stock worth $25,000 after purchasing an additional 241 shares during the last quarter. Bank & Trust Co purchased a new stake in shares of Morgan Stanley during the 2nd quarter worth $26,000. Finally, Bbjs Financial Advisors LLC purchased a new stake in Morgan Stanley in the second quarter valued at about $29,000. 84.19% of the stock is owned by hedge funds and other institutional investors.
Morgan Stanley Company Profile
Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals in the Americas, Europe, the Middle East, Africa, and Asia. It operates through Institutional Securities, Wealth Management, and Investment Management segments.
Further Reading
- Five stocks we like better than Morgan Stanley
- Business Services Stocks Investing
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- What Are Dividend Achievers? An Introduction
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Morgan Stanley Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morgan Stanley and related companies with MarketBeat.com's FREE daily email newsletter.